Craft

Gamida Cell

Stock Price

$0

2024-09-17

Market Capitalization

$4.3 M

2024-09-17

Revenue

$1.8 M

FY, 2023

Gamida Cell Summary

Company Summary

Overview
Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. The Company’s scientists have developed a broad platform technology to expand functional cells in culture to create life-saving cures for blood cancers such as leukemia and lymphoma and rare genetic diseases such as sickle cell disease.
Type
Public
Status
Active
Founded
1998
HQ
Boston, MA, US | view all locations
Website
http://www.gamida-cell.com/
Cybersecurity rating
Sectors

Key People

  • Michele Korfin

    Michele Korfin, Chief Operating and Chief Commercial Officer

    • Naftali Brikashvili, Senior Vice President, Finance and Operations

    • Kenneth Moch, Director

      • Stephen Wills, Director

        Operating MetricsView all

        Patients Reached

        120

        Q3, 2018

        LocationsView all

        2 locations detected

        • Boston, MA HQ

          United States

          673 Boylston St 4th Floor

        • Jerusalem, Jerusalem District

          Israel

        Gamida Cell Financials

        Summary Financials

        Revenue (Q1, 2024)
        $890.0K
        Gross profit (Q1, 2024)
        ($26.0K)
        Net income (Q1, 2024)
        ($19.9M)
        Cash (Q1, 2024)
        $24.8M
        EBIT (Q1, 2024)
        ($25.1M)
        Enterprise value
        $56.5M

        Footer menu